

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Dementia

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional equality issues were raised during the consultation period.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The wording of the recommendations have been changed following consultation however these changes have been to clarify the meaning of the recommendations and do not introduce any barriers or difficulties for people living with dementia or their families and carers accessing services.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

It is not envisioned that the wording of the recommendations will have an adverse impact on people with disabilities.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.2, 4.3 and 4.4, or otherwise fulfil NICE's obligations to advance equality?

The committee were not aware of any specific barriers to access for particular groups, in the context of initiation and review of Donepezil, Rivastigmine, Galantamine and Memantine for treatment of Alzheimer's Disease. It is hoped that the revised recommendations will improve access overall.

4.5 Have the Committee's considerations of equality issues been described in the final guideline document, and, if so, where?

Where appropriate the committee's considerations of equality issues have been described in the evidence to recommendations section of the guideline addendum.

Updated by Developer - Sue Spiers

Date 31/03/2016

Approved by NICE quality assurance lead Christine Carson

Date 8 April 2016

